Print

Purpose

The goal of this clinical trial is to develop an pharmacist-led preoperative opioid taper intervention for patients undergoing total knee or hip replacement who are on chronic opioids before their surgery. The main questions it aims to answer are: - Is the intervention feasible and acceptable to patients? - Does the intervention result in a decrease in opioid dose during the preoperative period? Participants will meet with a clinical pharmacist, who will provide some basic education on pain and opioids, and will propose an opioid taper schedule. The pharmacist will then follow-up with the participant by phone each week until surgery to assess progress and adjust the taper as necessary.

Conditions

Eligibility

Eligible Ages
Over 18 Years
Eligible Genders
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • decided to pursue primary, unilateral total knee or hip arthroplasty with planned surgery date in 4-8 weeks - currently taking between 20 and 90 MME of oral opioids, and that dose has been stable for at least 3 months - have a reliable telephone number for contact - speaks English

Exclusion Criteria

  • Taking opioid medications that include: - Buprenorphine - Methadone - Long-acting formulations of opioid pain medications (e.g., extended-release oxycodone and extended-release morphine) - Transdermal formations of opioid pain medications (e.g., fentanyl patches)

Study Design

Phase
N/A
Study Type
Interventional
Allocation
N/A
Intervention Model
Single Group Assignment
Primary Purpose
Supportive Care
Masking
None (Open Label)

Arm Groups

ArmDescriptionAssigned Intervention
Experimental
Pharmacist-led opioid taper intervention 		The participant will attempt to taper their opioid dose by ~50% during the 4-6 week preoperative period. Participants will meet with a clinical pharmacist, who will provide some basic education on pain and opioids, and will propose an opioid taper schedule. The pharmacist will then follow-up with the participant by phone each week until surgery to assess progress and adjust the taper as necessary.
  • Behavioral: opioid taper
    The participant will attempt to taper their opioid dose by ~50% during the 4-6 week preoperative period

Recruiting Locations

UAB Hospital-Highlands
Birmingham, Alabama 35205

More Details

Status
Recruiting
Sponsor
University of Alabama at Birmingham

Study Contact

Kevin R Riggs, MD
205-934-0778
kriggs@uabmc.edu

Notice

Study information shown on this site is derived from ClinicalTrials.gov (a public registry operated by the National Institutes of Health). The listing of studies provided is not certain to be all studies for which you might be eligible. Furthermore, study eligibility requirements can be difficult to understand and may change over time, so it is wise to speak with your medical care provider and individual research study teams when making decisions related to participation.